Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Mallinckrodt
AstraZeneca
Moodys
McKesson

Last Updated: June 10, 2023

Vancomycin - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for vancomycin and what is the scope of patent protection?

Vancomycin is the generic ingredient in eight branded drugs marketed by Xellia Pharms Aps, Ani Pharms, Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Azurity, Lederle, Alkem Labs Ltd, Steriscience, Baxter Hlthcare, Hikma, Aspiro, Emcure Pharms Ltd, Eugia Pharma, Gland Pharma Ltd, Hainan Poly, Hainan Poly Pharm, Hikma Pharms, Hospira, Hospira Inc, Knack, Meitheal, Mylan Labs Ltd, Pharm Assoc, Sagent Pharms, Sandoz, Sandoz Inc, Teva Pharms Usa, Pharmacia And Upjohn, and Samson Medcl, and is included in sixty NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vancomycin has forty-two patent family members in twenty-seven countries.

There are twenty-two drug master file entries for vancomycin. One supplier is listed for this compound.

Summary for vancomycin
International Patents:42
US Patents:11
Tradenames:8
Applicants:33
NDAs:60
Drug Master File Entries: 22
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 36
Clinical Trials: 421
Patent Applications: 5,180
Drug Prices: Drug price trends for vancomycin
What excipients (inactive ingredients) are in vancomycin?vancomycin excipients list
DailyMed Link:vancomycin at DailyMed
Drug Prices for vancomycin

See drug prices for vancomycin

Drug Sales Revenue Trends for vancomycin

See drug sales revenues for vancomycin

Recent Clinical Trials for vancomycin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universitätsmedizin MannheimPhase 2
German Cancer Research CenterPhase 2
Michael DillPhase 2

See all vancomycin clinical trials

Pharmacology for vancomycin

US Patents and Regulatory Information for vancomycin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride INJECTABLE;INJECTION 204360-001 Oct 15, 2018 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Mylan Labs Ltd VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride INJECTABLE;INJECTION 091469-001 Jul 1, 2011 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride CAPSULE;ORAL 065453-001 Jun 18, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Merck
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.